 CRANBURY, N.J., Feb. 16, 2021 GLOBE NEWSWIRE -- PMV Pharmaceuticals, Inc. Nasdaq: PMVP, a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced the appointment of Guillermina Gigi Lozano, Ph.D., to its Scientific Advisory Board SAB. 